ScripThe end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Shionogi Gets Daridorexant’s Japanese D
In VivoThe knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. 's patritumab deruxtecan (DXd) in June, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab
ScripAntibody-drug conjugates are big business and major deals have been struck in this area over the past year or so, with companies including Pfizer Inc. , Johnson & Johnson and Merck & Co., Inc. al